Loading…
Loading grant details…
| Funder | European Commission |
|---|---|
| Recipient Organization | Onego Bio Ltd |
| Country | Finland |
| Start Date | Jan 01, 2025 |
| End Date | Dec 31, 2026 |
| Duration | 729 days |
| Number of Grantees | 1 |
| Roles | Coordinator |
| Data Source | European Commission |
| Grant ID | 101188965 |
Eggs are critically important in the global food system due to functional and nutritional properties; yet the egg market and supply chains are in crisis due to cage-free requirements and avian flu. Onego Bio will make it possible to manufacture egg protein entirely animal-free.
We developed a highly-scalable precision fermentation process using the patented Trichoderma reesei cellular-based production to produce animal-free ovalbumin.
We produce bioidentical egg protein with cost parity and 87% lower CO2 emissions compared to traditional animal-derived eggs.Ovalbumin is the most important egg protein, responsible for the essential ingredient performance.
This single protein ovalbumin can solve all current challenges in the egg market and supply chain.Our product, Bioalbumen provides the nutritional and functional upsides of egg protein, without the environmental, ethical and safety-related drawbacks. Our manufacturing method stabilises the food supply chain and increases food security.
Onego Bio Ltd
Complete our application form to express your interest and we'll guide you through the process.
Apply for This Grant